Biosimilar to Remicade
Expected U.S. launch in 2023.
Pharma maker develops biosimilars to Lucentis, Eyelea.
Blockbuster drug could be key to Humira’s successor.
CD20-directed antibody indicated for several cancers and other conditions.
While FDA approved the second biosimilar drug to Enbrel, the success of the medication hinges on a pending lawsuit.
FDA approved the first biosimilar to rituximab (Rituxan, Genentech) to treat non-Hodgkin lymphoma.
FDA approved the first biosimilar to Neulasta, as well as a new combination treatment for osteoarthritis pain and hypertension and a new drug to treat chronic lymphocytic leukemia.
The top 3 new US drug approvals include the first non-opioid treatment for opioid withdrawal, a migraine prevention drug, and the first biosimilar for anemia. Here are the top 3 new drugs, approved within the last week.